. 2019 Nov 13;9:16662. doi: 10.1038/s41598-019-52944-6

Table 3.

Relationship between pathological complete response and clinicopathological factors including PD-L1 expression.

		Non-pCR	pCR	pCR ratio (%)	p
		Non-pCR	pCR	pCR ratio (%)	Univariate	Multivariate
PD-L1	Positive	3	19	86.4	0.027	0.34
PD-L1	Negative	40	64	61.5	0.027	0.34
TILs	40–90%	3	20	87.0	0.018	0.40
TILs	0–40%	40	63	61.2	0.018	0.40
CD8-positive TILs	High	26	61	70.1	0.18	—
CD8-positive TILs	Low	13	17	56.7	0.18	—
ER	Negative	15	62	80.5	<0.0001	0.058
ER	Positive	28	21	42.9	<0.0001	0.058
PgR	Negative	22	69	75.8	0.00015	0.25
PgR	Positive	21	14	40.0	0.00015	0.25
Ki67	High (≥30%)	24	66	73.3	0.0052	0.15
Ki67	Low (<30%)	19	17	47.2	0.0052	0.15
Histological grade	Grade 3	31	76	71.0	0.0038	0.28
Histological grade	Grade 1/2	12	7	36.8	0.0038	0.28
Clinical tumor size	cT 3/4	17	27	61.4	0.43	—
Clinical tumor size	cT 1/2	26	56	68.3	0.43	—
Clinical nodal status	Positive	29	56	65.9	1.00	—
Clinical nodal status	Negative	14	27	65.9	1.00	—

Abbreviations: PD-L1, programmed death-ligand 1; TILs, tumor-infiltrating infiltrating lymphocytes; ER, estrogen receptor; PgR, progesterone receptor; pCR, pathological complete response.